{"prompt": "['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', '15.', 'Musunuru HB, Klotz L, Vespirini D, et al. Cautionary tale of active surveillance in', 'intermediate-risk patients: Overall and cause-specific survival in the Sunnybrook', 'experience. 2015 Genitourinary Cancers Symposium; 2015; Orlando, FL.', '16.', 'Schweizer MT, Antonarakis ES. Abiraterone and other novel androgen-directed', 'strategies for the treatment of prostate cancer: a new era of hormonal therapies is born.', 'Ther Adv Urol 2012;4:167-78.', '17.', 'Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide', 'Study Group. The New England journal of medicine 1984;311:1281-6.', '18.', 'Scher HI, Heller G. Clinical states in prostate cancer: toward a dynamic model of', 'disease progression. Urology 2000;55:323-7.', '19.', 'Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in Metastatic Prostate', 'Cancer before Chemotherapy. The New England journal of medicine 2014.', '20.', 'de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in', 'metastatic prostate cancer. The New England journal of medicine 2011;364:1995-2005.', '21.', 'Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer', 'without previous chemotherapy. The New England journal of medicine 2013;368:138-48.', '22.', 'Rathkopf DE, Danila DC, Morris MJ, et al. Phase I/II safety and pharmacokinetic (PK)', 'study of ARN-509 in patients with metastatic castration-resistant prostate cancer', '(mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium study.', 'Genitourinary Cancers Symposium; 2012; San Francisco, CA.', '23.', 'Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate', 'cancer before chemotherapy. The New England journal of medicine 2014;371:424-33.', '24.', 'Rathkopf D, Scher HI. Androgen receptor antagonists in castration-resistant', 'prostate cancer. Cancer J 2013;19:43-9.', '25.', 'Taplin ME, Montgomery B, Logothetis CJ, et al. Intense androgen-deprivation', 'therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk', 'prostate cancer: results of a randomized phase II neoadjuvant study. Journal of clinical', 'oncology : official journal of the American Society of Clinical Oncology 2014;32:3705-15.', '26.', 'Gulley JL, Aragon-Ching JB, Steinberg SM, et al. Kinetics of serum androgen', 'normalization and factors associated with testosterone reserve after limited androgen', 'deprivation therapy for nonmetastatic prostate cancer. The Journal of urology', '2008;180:1432-7; discussion 7.', '27.', 'Tunn UW, Canepa G, Kochanowsky A, Kienle E. Testosterone recovery in the off-', 'treatment time in prostate cancer patients undergoing intermittent androgen deprivation', 'therapy. Prostate cancer and prostatic diseases 2012;15:296-302.', '28.', 'Yoon FH, Gardner SL, Danjoux C, Morton G, Cheung P, Choo R. Testosterone recovery', 'after prolonged androgen suppression in patients with prostate cancer. The Journal of', 'urology 2008;180:1438-43; discussion 43-4.', '29. Schweizer MT, Huang P, Kattan MW, et al. Adjuvant leuprolide with or without', 'docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-', '3501): important lessons for future trials. Cancer 2013;119:3610-8.', '30.', 'Roach M, 3rd, Thomas K. Overview of randomized controlled treatment trials for', 'clinically localized prostate cancer: implications for active surveillance and the United', '72', 'Printed on 1/29/2021']['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', 'States preventative task force report on screening? J Natl Cancer Inst Monogr', '2012;2012:221-9.', '31.', 'Eri LM, Urdal P, Bechensteen AG. Effects of the luteinizing normone-releasing', 'hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator', 'inhibitor in patients with benign prostatic hyperplasia. The Journal of urology', '1995;154:100-4.', \"32. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during\", 'androgen deprivation therapy for prostate cancer. Journal of clinical oncology : official', 'journal of the American Society of Clinical Oncology 2006;24:4448-56.', '33.', 'Smith MR, Lee H, McGovern F, et al. Metabolic changes during gonadotropin-', 'releasing hormone agonist therapy for prostate cancer: differences from the classic', 'metabolic syndrome. Cancer 2008;112:2188-94.', '34.', 'Smith MR, Saad F, Egerdie B, et al. Sarcopenia during androgen-deprivation therapy', 'for prostate cancer. Journal of clinical oncology : official journal of the American Society of', 'Clinical Oncology 2012;30:3271-6.', '35.', 'Bruchovsky N, Klotz L, Crook J, Goldenberg SL. Locally advanced prostate cancer--', 'biochemical results from a prospective phase II study of intermittent androgen', 'suppression for men with evidence of prostate-specific antigen recurrence after', 'radiotherapy. Cancer 2007;109:858-67.', '36.', 'Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: a novel antiandrogen for prostate', 'cancer treatment. Cancer research 2012;72:1494-503.', '37. Foster WR, Car BD, Shi H, et al. Drug safety is a barrier to the discovery and', 'development of new androgen receptor antagonists. Prostate 2011;71:480-8.', '38.', 'Smith MR, Antonarakis ES, Ryan CJ, et al. ARN-509 in men with high-risk', 'nonmetastatic castration-resistant prostate cancer (CRPC). Genitourinary Cancers', 'Symposium; 2013; Orlando, FL.', '39.', 'Smith MR, Saad F, Chowdhury S, et al. Apalutamide Treatment and Metastasis-free', 'Survival in Prostate Cancer. The New England journal of medicine 2018.', '40.', \"D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical\", 'prostatectomy, external beam radiation therapy, or interstitial radiation therapy for', 'clinically localized prostate cancer. Jama 1998;280:969-74.', '41.', 'Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to', 'predict tumor extent of nonpalpable (stage T1c) prostate cancer. Jama 1994;271:368-74.', '42.', 'Mohler JL. The 2010 NCCN clinical practice guidelines in oncology on prostate', 'cancer. Journal of the National Comprehensive Cancer Network : JNCCN 2010;8:145.', '43.', 'Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low', 'risk prostate cancer: risk assessment and treatment. The Journal of urology 2007;178:S14-', '9.', '44.', 'Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin', '2013;63:11-30.', '45.', 'Soloway MS, Soloway CT, Eldefrawy A, Acosta K, Kava B, Manoharan M. Careful', 'selection and close monitoring of low-risk prostate cancer patients on active surveillance', 'minimizes the need for treatment. European urology 2010;58:831-5.', '73', 'Printed on 1/29/2021']\n\n###\n\n", "completion": "END"}